Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381664 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants
A Phase 1 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03381664 is a Phase 1 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT03381664, a Phase 1 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the relative bioavailability, pharmacokinetics, safety, and tolerability of AVP-923 (dextromethorphan hydrobromide \[DM\] and quinidine sulfate \[Q\] capsules) when the contents of a capsule are administered in applesauce or via a nasogastric feeding tube, compared with administration of a capsule in healthy, fasting, adult participants.
Interventions
- DRUG AVP-923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2018-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03381664
The ClinicalTrials.gov registry entry for NCT03381664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVP-923 is the first listed.
NCT03381664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03381664 about?
NCT03381664 is a clinical study titled "Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants". This study will be conducted to evaluate the relative bioavailability, pharmacokinetics, safety, and tolerability of AVP-923 (dextromethorphan hydrobromide \[DM\] and quinidine sulfate \[Q\] capsules) when the contents of a capsule are administered in applesauce or via a nasogastric feeding tube, co...
What is the current status of trial NCT03381664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-11-28. Estimated completion is 2018-01-30.
What interventions are being tested in trial NCT03381664?
The interventions under investigation include: AVP-923 (DRUG).
Who is sponsoring clinical trial NCT03381664?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.